Suggested remit: To appraise the clinical and cost effectiveness of remdesivir within its marketing authorisation for treating coronavirus disease 2019 (COVID-19) in people with pneumonia requiring supplemental oxygen.
Status Awaiting development
Decision None selected
Process TA

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
06 October 2020 (10:00) Scoping workshop
18 August 2020 - 16 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual